magolibero
..se la sà gira..
Viralic potresti chiedere a Garufi se questa fase II indicata da Magolibero è roba nostra ?
ma cosa vuoi che gli risponda di diverso dal leggersi l'ultimo comunicato congiunto ?
http://www.nicox.com/files/pdf/PR2012031300EN.pdf
13 March 2012 - Sophia Antipolis, France and Madison, NJ, USA. Bausch + Lomb, the global eye health company, and NicOx S.A. (NYSE Euronext Paris: COX) today announced positive top-line results from the phase 2b study conducted with BOL-303259-X, a novel nitric oxide-donating prostaglandin F2-alpha analog, in patients with open-angle glaucoma or ocular hypertension. BOL-303259-X (previously NCX 116) was licensed by NicOx to Bausch + Lomb in March 2010 (see NicOx and Bausch + Lomb press release dated March 3, 2010). Bausch + Lomb will pay a $10 million milestone payment to NicOx and will initiate a global phase 3 development program for BOL-303259-X.